Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development
Enrolled four patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q2 2026, bringing the total number of enrolled patients to 66, with a total of
Zevra is testing a new medicine for a rare disease and has enrolled 66 patients so far in their study. The company plans to talk with the FDA later this year about ways to move their medicine development forward faster.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.